CLYM

NEUTRALAnalyst

Climb Bio, Inc.

2026-07-21

Price

$13.10

+7.20%

This is the 2026-07-21 snapshot — the signals and analysis for CLYM as of this single trading day.

View full CLYM research hub →

Score10.5Top Tier

Signals3/8 DNA3/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.0xvs 20d avg

Analysis

CLYM is exhibiting High-Conviction Price Discovery, surging 7.2% today after BTIG reaffirmed a $20 price target highlighting the scarcity premium of its CLYM116 asset in a $20B market. This bullish fundamental analyst catalyst ignited a BOLLINGER_SQUEEZE and PERFECT_STACK technical setup, confirming the QUIET_ACCUMULATION phase recently validated by Fidelity's disclosure of a massive 6.8 million share stake. With the macro regime firmly RISK_ON—evidenced by exceptionally tight credit spreads (0.78%) despite geopolitical noise—the environment is perfectly insulated for high-beta biotech assets to attract aggressive institutional capital.

Fired Signals

GOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKQUIET ACCUMULATIONSTOCHASTIC POPINSIDE OUT

Key Takeaways

Actionable Thesis: Go long CLYM to capitalize on the Bollinger Squeeze breakout, fundamentally supported by a $20 BTIG price target and heavy institutional sponsorship.
Key Risk: As a clinical-stage biotech, CLYM is highly sensitive to any adverse pipeline developments or sudden macro liquidity shocks that could reverse risk-on sentiment.
What to Watch: Price action around the $12.22 support level to confirm the structural integrity of the current institutional accumulation trend.

← Back to 2026-07-21 View Full CLYM History →Yahoo Finance &nearr;